1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
Book a demo
-
  1. My Preqin
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
  1. My Preqin
Book a demo

Touchlight Genetics Ltd.

Have updates for this profile?  Please contribute data

About
= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2008

Location

London UK

Primary Industry

Biotechnology

About

Based in London, UK, and founded in 2008, Touchlight Genetics Ltd. develops DNA vaccine and non-viral gene therapy assets. The company was founded by Jonny Ohlson, its CEO. In December 2017, the company raised its latest grant funding led by Innovate UK. The company's products include dbDNA or doggyboneDNA vector that offers complete design control with the ability to encode very large and unstable sequences. The company's platform uses enzymatic technology that helps to produce DNA vaccines for oncology and infectious diseases.
Current Investors
Downing, Innovate UK, Bridford Investments Ltd.

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.touchlight.com
Verticals
Manufacturing
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.
Sign in Request demo